We are a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation (“I&I”) and fundamentally improve patient quality of life. Although monoclonal antibodies have transformed the I&I treatment landscape, many patients remain underserved, continuing to experience incomplete responses or residual disease activity. We believe that next-generation therapeutic approaches, particularly bispecific and multi-target biologics that simultaneously modulate complementary and synergistic inflammatory pathways, are necessary to expand responder populations, address the significant unmet medical need, and unify treatment across overlapping disease biology.